Timolol
- Generic Name
- Timolol
- Brand Names
- Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom
- Drug Type
- Small Molecule
- Chemical Formula
- C13H24N4O3S
- CAS Number
- 26839-75-8
- Unique Ingredient Identifier
- 5JKY92S7BR
- Background
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
- Indication
Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)
Topical Timolol for Superficial Infantile Hemangioma
- Conditions
- Hemangioma
- Interventions
- Drug: Normal saline
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 48
- Registration Number
- NCT01685398
- Locations
- 🇹🇭
Faculty of Medicine Siriraj Hospital Mahidol University, Bangkoknoi, Bangkok, Thailand
24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension
- Conditions
- Ocular Hypertension
- Interventions
- Drug: timolol-dorzolamide fixed combination
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- University of Parma
- Target Recruit Count
- 61
- Registration Number
- NCT01655758
- Locations
- 🇮🇹
University Eye Clinic, Parma, Italy
Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%
- Conditions
- Optic Neuropathy, IschemicIschemic Optic NeuropathyAnterior Ischemic Optic NeuropathyOptic Neuropathy, Anterior Ischemic
- Interventions
- First Posted Date
- 2012-05-30
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- Fraser Health
- Registration Number
- NCT01607671
- Locations
- 🇨🇦
Jim Pattison Outpatient Care and Surgery Centre, 3C Neurology, Surrey, British Columbia, Canada
Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol
- Conditions
- Sturge Weber SyndromePort-wine Mark
- Interventions
- Drug: Preservative free artificial tear gel.
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Wills Eye
- Target Recruit Count
- 3
- Registration Number
- NCT01533376
- Locations
- 🇺🇸
Wills Eye Institute, Philadelphia, Pennsylvania, United States
Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension
- Conditions
- Primary Open Angle GlaucomaOcular Hypertension
- Interventions
- Drug: Stage 1 - ATS907 - Dose 2Drug: Stage 1 - ATS907 - Dose 1Drug: Stage 1 - ATS907 - Dose 4Drug: Stage 1 - VehicleDrug: Stage 2 - ATS907 - Dose A - to be selected based on Stage 1Drug: Stage 2 - ATS907 - Dose B - to be selected based on Stage 1Drug: Stage 1 - ATS907 - Dose 3
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Altheos, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT01520116
Effect of Timolol on Refractive Outcomes in Eyes With Myopic Regression After LASIK: a Randomized Clinical Trial
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2012-01-10
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 45
- Registration Number
- NCT01506635
- Locations
- 🇮🇷
Ophthalmic Research Center, Tehran, Iran, Islamic Republic of
Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma
- Conditions
- Normal Tension Glaucoma
- Interventions
- Drug: Brimonidine/Timolol mixed combination
- First Posted Date
- 2011-10-05
- Last Posted Date
- 2011-10-05
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT01446497
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)
- Conditions
- Very Low Birth Weight InfantsInfantile Hemangioma
- Interventions
- Drug: Control (placebo) group
- First Posted Date
- 2011-09-15
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- Alice K. Gong
- Target Recruit Count
- 26
- Registration Number
- NCT01434849
- Locations
- 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma
- Conditions
- Glaucoma
- Interventions
- First Posted Date
- 2011-08-31
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Allergan
- Target Recruit Count
- 6
- Registration Number
- NCT01426113
Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)
- Conditions
- Infantile Hemangiomas
- Interventions
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2014-01-17
- Lead Sponsor
- Children's Hospital of Philadelphia
- Registration Number
- NCT01408056
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.